Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.

Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK.

Cell Growth Differ. 2001 Jul;12(7):363-9.

2.

HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases.

Michiels C, Minet E, Michel G, Mottet D, Piret JP, Raes M.

IUBMB Life. 2001 Jul;52(1-2):49-53. Review.

3.

Introduction: multifaceted roles of lipids and their catabolites in immune cell signaling.

Ott VL, Cambier JC.

Semin Immunol. 2002 Feb;14(1):1-6. Review. No abstract available.

PMID:
11884225
4.

Regulation of translation initiation by FRAP/mTOR.

Gingras AC, Raught B, Sonenberg N.

Genes Dev. 2001 Apr 1;15(7):807-26. Review. No abstract available.

5.

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J.

Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41. Review.

PMID:
11706404
6.

Restraining PI3K: mTOR signalling goes back to the membrane.

Harrington LS, Findlay GM, Lamb RF.

Trends Biochem Sci. 2005 Jan;30(1):35-42. Review.

PMID:
15653324
7.

Signal transduction to hypoxia-inducible factor 1.

Semenza G.

Biochem Pharmacol. 2002 Sep;64(5-6):993-8. Review.

PMID:
12213597
8.

Synthesis and function of 3-phosphorylated inositol lipids.

Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD.

Annu Rev Biochem. 2001;70:535-602. Review.

PMID:
11395417
9.
10.

Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).

Blagosklonny MV.

Int J Oncol. 2001 Aug;19(2):257-62. Review.

PMID:
11445836
11.

Phosphoinositide 3-kinase and INPP4B in human breast cancer.

Bertucci MC, Mitchell CA.

Ann N Y Acad Sci. 2013 Mar;1280:1-5. doi: 10.1111/nyas.12036. Review.

PMID:
23551093
12.

The role of PTEN in allergic inflammation.

Lee YC.

Arch Immunol Ther Exp (Warsz). 2004 Jul-Aug;52(4):250-4. Review.

PMID:
15467489
13.

PI3K pathway alterations in cancer: variations on a theme.

Yuan TL, Cantley LC.

Oncogene. 2008 Sep 18;27(41):5497-510. doi: 10.1038/onc.2008.245. Review.

14.

To differentiate or proliferate? The interaction between PI3K/PTEN and Cdx2.

Lynch JP, Silberg DG.

Gastroenterology. 2002 Oct;123(4):1395-7. Review. No abstract available.

PMID:
12360502
15.

Hypoxia inducible factor-1: a novel target for cancer therapy.

Belozerov VE, Van Meir EG.

Anticancer Drugs. 2005 Oct;16(9):901-9. Review.

PMID:
16162966
16.

Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases.

Leslie NR, Dixon MJ, Schenning M, Gray A, Batty IH.

Adv Biol Regul. 2012 Jan;52(1):205-13. Review. No abstract available.

PMID:
21930147
17.

Cancer genes and the pathways they control.

Vogelstein B, Kinzler KW.

Nat Med. 2004 Aug;10(8):789-99. Review.

PMID:
15286780
18.

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors.

Mellinghoff IK, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81. Review.

19.

Phosphoinositide 3-kinase inhibition in cancer treatment.

Berrie CP.

Expert Opin Investig Drugs. 2001 Jun;10(6):1085-98. Review.

PMID:
11772237
20.

The tumor microenvironment in non-small-cell lung cancer.

Graves EE, Maity A, Le QT.

Semin Radiat Oncol. 2010 Jul;20(3):156-63. doi: 10.1016/j.semradonc.2010.01.003. Review.

Supplemental Content

Support Center